Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

Authors: Nicholas A. Turner, Smitha Zaharoff, Heather King, Scott Evans, Toshimitsu Hamasaki, Thomas Lodise, Varduhi Ghazaryan, Tatiana Beresnev, Todd Riccobene, Rinal Patel, Sarah B. Doernberg, Urania Rappo, Vance G. Fowler, Thomas L. Holland, on behalf of the Antibacterial Resistance Leadership Group (ARLG)

Source: Trials, Vol 23, Iss 1, Pp 1-15 (2022)

Subject Terms: Staphylococcus aureus, Bacteremia, Right-sided endocarditis, Dalbavancin, Randomized controlled trial, Medicine (General), R5-920

File Description: electronic resource

Relation: https://doaj.org/toc/1745-6215

Access URL: https://doaj.org/article/a09ef7c8d4244ac5b80e26defc820dae

Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa : PRIMERS IV

Authors: Antibacterial Resistance Leadership Group (ARLG), Evans, Scott R., Tran, Thuy Tien T., Hujer, Andrea M., Hill, Carol B., Hujer, Kristine M., Mediavilla, Jose R., Manca, Claudia, Domitrovic, T. Nicholas, Perez, Federico, Farmer, Michael, Pitzer, Kelsey M., Wilson, Brigid M., Kreiswirth, Barry N., Patel, Robin, Jacobs, Michael R., Chen, Liang, Fowler, Vance G., Chambers, Henry F., Bonomo, Robert A.

Source: Clinical Infectious Diseases, 2019 Jun 01. 68(11), 1823-1830.

Access URL: https://www.jstor.org/stable/26641268

The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress

Authors: Antibacterial Resistance Leadership Group (ARLG), Chambers, Henry F. "Chip", Cross, Heather R., Evans, Scott R., Kreiswirth, Barry N., Fowler, Vance G.

Source: Clinical Infectious Diseases, 2017 Mar . 64, S3-S7.

Access URL: https://www.jstor.org/stable/26373886

Transforming Concepts Into Clinical Trials and Creating a Multisite Network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group

Authors: Leadership and Operations Center of the Antibacterial Resistance Leadership Group (ARLG), Cross, Heather R., Harris, Anthony, Arias, Rebekka M., Chambers, Henry F. "Chip", Jr, Vance G. Fowler

Source: Clinical Infectious Diseases, 2017 Mar . 64, S8-S12.

Access URL: https://www.jstor.org/stable/26373887

Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group

Authors: Laboratory Center of the Antibacterial Resistance Leadership Group (ARLG), Manca, Claudia, Hill, Carol, Hujer, Andrea M., Patel, Robin, Evans, Scott R., Bonomo, Robert A., Kreiswirth, Barry N.

Source: Clinical Infectious Diseases, 2017 Mar . 64, S13-S17.

Access URL: https://www.jstor.org/stable/26373888

Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group

Authors: Statistical and Data Management Center of the Antibacterial Resistance Leadership Group (ARLG), Huvane, Jacqueline, Komarow, Lauren, Hill, Carol, Tran, Thuy Tien T., Pereira, Carol, Rosenkranz, Susan L., Finnemeyer, Matt, Earley, Michelle, Jiang, Hongyu (Jeanne), Wang, Rui, Lok, Judith, Evans, Scott R.

Source: Clinical Infectious Diseases, 2017 Mar . 64, S18-S23.

Access URL: https://www.jstor.org/stable/26373889

Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group

Authors: Gram-Negative Committee of the Antibacterial Resistance Leadership Group (ARLG), Doi, Yohei, Bonomo, Robert A., Hooper, David C., Kaye, Keith S., Johnson, James R., Clancy, Cornelius J., Thaden, Joshua T., Stryjewski, Martin E., van Duin, David

Source: Clinical Infectious Diseases, 2017 Mar . 64, S30-S35.

Access URL: https://www.jstor.org/stable/26373891

The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group

Authors: Stewardship and Infection Control Committeea of the Antibacterial Resistance Leadership Group (ARLG), Anderson, Deverick J., Jenkins, Timothy C., Evans, Scott R., Harris, Anthony D., Weinstein, Robert A., Tamma, Pranita D., Han, Jennifer H., Banerjee, Ritu, Patel, Robin, Zaoutis, Theoklis, Lautenbach, Ebbing

Source: Clinical Infectious Diseases, 2017 Mar . 64, S36-S40.

Access URL: https://www.jstor.org/stable/26373892

MASTERMIND: Bringing Microbial Diagnostics to the Clinic

Authors: Antibacterial Resistance Leadership Group (ARLG), Patel, Robin, Tsalik, Ephraim L., Petzold, Elizabeth, Fowler, Vance G., Klausner, Jeffrey D., Evans, Scott

Source: Clinical Infectious Diseases, 2017 Feb 01. 64(3), 355-360.

Access URL: https://www.jstor.org/stable/26373673

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.

Authors: Turner, Nicholas A., Zaharoff, Smitha, King, Heather, Evans, Scott, Hamasaki, Toshimitsu, Lodise, Thomas, Ghazaryan, Varduhi, Beresnev, Tatiana, Riccobene, Todd, Patel, Rinal, Doernberg, Sarah B., Rappo, Urania, Fowler Jr, Vance G., Holland, Thomas L., Fowler, Vance G Jr, Antibacterial Resistance Leadership Group (ARLG)

Source: Trials; 5/16/2022, Vol. 23 Issue 1, p1-15, 15p, 1 Diagram, 2 Charts